Characteristics of ITP
| Characteristics . | N = 28 . | |||
|---|---|---|---|---|
| At the time of TPO-RA introduction . | At the end of study . | |||
| ITP duration (y) | 4 | (0-24) | ||
| Chronic or persistent ITP | 22 | (78.6%) | 28 | (100%) |
| Indication of antiplatelet drugs or anticoagulant | 2 | (7.1%) | 4 | (14.3%) |
| Immunoglobulin replacement therapy | 11 | (39.3%) | 22 | (78.6%) |
| Second-line therapies for ITP | 10 | (35.7%) | 7 | (25.0%) |
| Immunosuppressants | 5 | (17.9%) | 5 | (17.9%) |
| Splenectomy | 2 | (7.1%) | 4 | (14.3%) |
| Rituximab received at least once | 5 | (17.9%) | 14 | (50.0%) |
| Characteristics . | N = 28 . | |||
|---|---|---|---|---|
| At the time of TPO-RA introduction . | At the end of study . | |||
| ITP duration (y) | 4 | (0-24) | ||
| Chronic or persistent ITP | 22 | (78.6%) | 28 | (100%) |
| Indication of antiplatelet drugs or anticoagulant | 2 | (7.1%) | 4 | (14.3%) |
| Immunoglobulin replacement therapy | 11 | (39.3%) | 22 | (78.6%) |
| Second-line therapies for ITP | 10 | (35.7%) | 7 | (25.0%) |
| Immunosuppressants | 5 | (17.9%) | 5 | (17.9%) |
| Splenectomy | 2 | (7.1%) | 4 | (14.3%) |
| Rituximab received at least once | 5 | (17.9%) | 14 | (50.0%) |
| Characteristics . | In the month before TPO-RA introduction . | During the treatment with TPO-RA . | ||
|---|---|---|---|---|
| Patients reporting bleeding events | 16 | (57.1%) | 10 | (35.7%) |
| Patients reporting bleeding events with Khellaf score >8 | 6 | (21.4%) | 2 | (7.1%) |
| Characteristics . | In the month before TPO-RA introduction . | During the treatment with TPO-RA . | ||
|---|---|---|---|---|
| Patients reporting bleeding events | 16 | (57.1%) | 10 | (35.7%) |
| Patients reporting bleeding events with Khellaf score >8 | 6 | (21.4%) | 2 | (7.1%) |
Quantitative variables are presented as median (range, minimum to maximum); and qualitative variables as frequency (percentage).
Median age at PID diagnosis was similar across these 4 populations.
NS, not specified.